Lithium decreases plasma adiponectin levels in bipolar depression

Neuroscience Letters

Volumn 564, Issue , 2014, Pages 111-114

  Soeiro de Souza, Márcio Gerhardt ^a   Gold, Philip W ^b   Brunoni, Andre R ^a   de Sousa, Rafael T ^a   Zanetti, Marcus V ^a   Carvalho, André F ^c   Gattaz, Wagner Farid ^a   Machado Vieira, Rodrigo ^a,b   Teixeira, AntÔnio Lúcio ^d  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^d University of Minas Gerais   (Brazil)

Author keywords

Adiponectin; Bipolar; Depression; Disorder; Lithium; Metabolic; Treatment

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; LEPTIN; LITHIUM; RESISTIN; ADIPOQ PROTEIN, HUMAN; NEUROLEPTIC AGENT; RETN PROTEIN, HUMAN;

ADIPOSE TISSUE; ADULT; ARTICLE; BIPOLAR DEPRESSION; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; ENERGY EXPENDITURE; FEMALE; FOLLOW UP; HAMILTON SCALE; HUMAN; INFLAMMATION; LITHIUM BLOOD LEVEL; MALE; METABOLIC SYNDROME X; MONOTHERAPY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT DURATION; WEIGHT GAIN; WEIGHT REDUCTION; BIPOLAR DISORDER; BLOOD; YOUNG ADULT;

ADIPONECTIN; ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; FEMALE; HUMANS; LEPTIN; LITHIUM; MALE; RESISTIN; YOUNG ADULT;

EID: 84896070315     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2014.02.005     Document Type: Article

References (31)

1. Yim C.Y., Soczynska J.K., Kennedy S.H., Woldeyohannes H.O., Brietzke E., McIntyre R.S. The effect of overweight/obesity on cognitive function in euthymic individuals with bipolar disorder. Eur. Psychiatry 2012, 27(April (3)):223-228.
2. Hert D.E.M., Schreurs V., Vancampfort D., van Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 2009, 8(February (1)):15-22.
3. Yatham L.N., Kennedy S.H., Parikh S.V., Schaffer A., Beaulieu S., Alda M., Milev R., Vieta E., Calabrese J.R., Berk M., Ha K., Kapczinski F. Canadian network for mood and anxiety treatments (CANMAT) and international society for bipolar disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013, 15(February (1)):1-44.
4. McElroy S.L., Kotwal R., Malhotra S., Nelson E.B., Keck P.E., Nemeroff C.B. Are mood disorders and obesity related? A review for the mental health professional. J. Clin. Psychiatry 2004, 65(May (5)). 634-51-quiz730.
5. McElroy S.L. Obesity in patients with severe mental illness: overview and management. J. Clin. Psychiatry 2009, 70(Suppl. 3):12-21.
6. Goodwin F.K., Jamison K.R. Manic-Depressive Illness: Bipolar and Recurrent Unipolar Disorders Second 2007, Oxford University Press, New York.
7. Fagiolini A., Frank E., Scott J.A., Turkin S., Kupfer D.J. Metabolic syndrome in bipolar disorder: findings from the bipolar disorder center for Pennsylvanians. Bipolar Disord. 2005, 7(October (5)):424-430.
8. Peselow E.D., Dunner D.L., Fieve R.R., Lautin A. Lithium carbonate and weight gain. J. Affect Disord. 1980, 2(December (4)):303-310.
9. Fagiolini A., Kupfer D.J., Houck P.R., Novick D.M., Frank E. Obesity as a correlate of outcome in patients with bipolar I disorder. Am. J. Psychiatry 2003, 160(January (1)):112-117.
10. Torrent C., Amann B., Sánchez-Moreno J., Colom F., Reinares M., Comes M., Rosa A.R., Scott J., Vieta E. Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. Acta Psychiatr. Scand. 2008, 118(July (1)):4-18.
11. Kemp D.E., Gao K., Chan P.K., Ganocy S.J., Findling R.L., Calabrese J.R. Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome. Bipolar Disord. 2010, 12(June (4)):404-413.
12. Livingstone C., Rampes H. Lithium: a review of its metabolic adverse effects. J. Psychopharmacol. (Oxford) 2006, 20(May (3)):347-355.
13. Ouchi N., Kihara S., Funahashi T., Matsuzawa Y., Walsh Obesity K. Adiponectin and vascular inflammatory disease. Curr. Opin. Lipidol. 2003, 14(December (6)):561-566.
14. Berg A.H., Scherer P.E. Adipose tissue, inflammation, and cardiovascular disease. Circ. Res. 2005, 96(May (9)):939-949.
15. Ouchi N., Parker J.L., Lugus J.J., Walsh K. Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 2011, 11(February (2)):85-97.
16. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372(December (6505)):425-432.
17. Elmquist J.K., Bjørbaek C., Ahima R.S., Flier J.S., Saper C.B. Distributions of leptin receptor mRNA isoforms in the rat brain. J. Comp. Neurol. 1998, 395(June (4)):535-547.
18. Lu X.-Y. The leptin hypothesis of depression: a potential link between mood disorders and obesity?. Curr. Opin. Pharmacol. 2007, 7(December (6)):648-652.
19. Lu X.-Y., Kim C.S., Frazer A., Zhang W. Leptin: a potential novel antidepressant. Proc. Natl. Acad. Sci. USA 2006, 103(January (5)):1593-1598.
20. Jow G.-M., Yang T.-T., Chen C.-L. Leptin and cholesterol levels are low in major depressive disorder, but high in schizophrenia. J. Affect. Disord. 2006, 90(January (1)):21-27.
21. Kraus T., Haack M., Schuld A., Hinze-Selch D., Pollmächer T. Low leptin levels but normal body mass indices in patients with depression or schizophrenia. Neuroendocrinology 2001, 73(April (4)):243-247.
22. Atmaca M., Kuloglu M., Tezcan E., Ustundag B., Bayik Y. Serum leptin and cholesterol levels in patients with bipolar disorder. Neuropsychobiology 2002, 46(4):176-179.
23. Steppan C.M., Bailey S.T., Bhat S., Brown E.J., Banerjee R.R., Wright C.M., Patel H.R., Ahima R.S., Lazar M.A. The hormone resistin links obesity to diabetes. Nature 2001, 409(January (6818)):307-312.
24. Jamaluddin M.S., Weakley S.M., Yao Q., Chen C. Resistin: functional roles and therapeutic considerations for cardiovascular disease. Br. J. Pharmacol. 2012, 165(February (3)):622-632.
25. Brunetti L., Orlando G., Recinella L., Michelotto B., Ferrante C., Vacca Resistin M. Resistin, but not adiponectin, inhibits dopamine and norepinephrine release in the hypothalamus. Eur. J. Pharmacol. 2004, 493(June (1-3)):41-44.
26. Lehto S.M., Huotari A., Niskanen L., Tolmunen T., Koivumaa-Honkanen H., Honkalampi K., Ruotsalainen H., Herzig K.H., Viinamäki H., Hintikka J. Serum adiponectin and resistin levels in major depressive disorder. Acta Psychiatr. Scand. 2010, 121(March (3)):209-215.
27. Ahima R.S. Metabolic actions of adipocyte hormones: focus on adiponectin. Obesity (Silver Spring) 2006, 14(February (Suppl. 1)):9S-15S.
28. Lee E.B., Warmann G., Dhir R., Ahima R.S. Metabolic dysfunction associated with adiponectin deficiency enhances kainic acid-induced seizure severity. J. Neurosci 2011, 31(October (40)):14361-14366.
29. Cizza G., Nguyen V.T., Eskandari F., Duan Z., Wright E.C., Reynolds J.C., Ahima R.S., Blackman M.R. Low 24-hour adiponectin and high nocturnal leptin concentrations in a case-control study of community-dwelling premenopausal women with major depressive disorder: the Premenopausal, Osteopenia/Osteoporosis, women, alendronate, depression (POWER) study. J. Clin. Psychiatry 2010, 71(August (8)):1079-1087.
30. Leo R., Di Lorenzo G., Tesauro M., Cola C., Fortuna E., Zanasi M., Troisi A., Siracusano A., Lauro R., Romeo F. Decreased plasma adiponectin concentration in major depression. Neurosci. Lett. 2006, 407(October 30 (3)):211-213.
31. Barbosa I.G., Rocha N.P., de Miranda A.S., Magalhães P.V.D.S., Huguet R.B., de Souza L.P., Kapczinski F., Teixeira A.L. Increased levels of adipokines in bipolar disorder. J. Psychiatr. Res. 2012, 46(March (3)):389-393.